Articles dans des revues avec comité de lecture (87)
27.
Brenard, E., Pilette, C., Dahlqvist, C., Colinet, B., Schleich, F. N. I. F., Roufosse, F., & Froidure, A. (2020). Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia. Lung, 198(2), 355-360. doi:10.1007/s00408-020-00336-328.
Roufosse, F., Kahn, J.-E., Rothenberg, M., Wardlaw, A., Klion, A., Kirby, S. Y., Gilson, M. M., Bentley, J. J., Bradford, E. E., Yancey, S. S., Steinfeld, J., & Gleich, G. (2020). Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. Journal of allergy and clinical immunology. doi:10.1016/j.jaci.2020.08.03730.
Khoury, P., Akuthota, P., Ackerman, S. S., Arron, J. J., Bochner, B. B., Collins, M. M., Kahn, J.-E., Fulkerson, P. P., Gleich, G. G., Gopal-Srivastava, R., Jacobsen, E. E., Leiferman, K., Francesca, L. S., Mathur, S. S., Minnicozzi, M., Prussin, C., Rothenberg, M., Roufosse, F., Sable, K., Simon, D., Simon, H.-U., Spencer, L. L., Steinfeld, J., Wardlaw, A., Wechsler, M. M., Weller, P., & Klion, A. (2018). Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD). Journal of leukocyte biology, 104(1), 69-83. doi:10.1002/JLB.5MR0118-028R33.
Wechsler, M., Akuthota, P., Jayne, D. R., Khoury, P., Klion, A., Langford, C. A., Merkel, P. P., Moosig, F., Specks, U., Cid, M. M., Luqmani, R., Brown, J., Mallett, S., Philipson, R., Yancey, S. S., Steinfeld, J., Weller, P. F., Gleich, G. J., EGPA Mepolizumab Study Team,, Roufosse, F., et al. (2017). Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. The New England journal of medicine, 376(20), 1921-1932. doi:10.1056/NEJMoa170207934.
Garaud, S., Roufosse, F., De Silva, P., Gu-Trantien, C., Lodewyckx, J. N., Duvillier, H., Dedeurwaerder, S., Bizet, M., Defrance, M., Fuks, F., Bex, F., & Willard-Gallo, K. (2017). FOXP1 is a regulator of quiescence in healthy human CD4+ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders. European Journal of Immunology, 47(1), 168-179. doi:10.1002/eji.20164637336.
Roufosse, F., Heimann, P., Lambert, F., Sidon, P., Bron, D., Cottin, V., & Cordier, J.-F. (2016). Severe prolonged cough as presenting manifestation of fip1l1-pdgfra + chronic eosinophilic leukaemia: A widely ignored association. Respiration, 91(5), 374-379. doi:10.1159/00044607637.
Bromberg, L., Roufosse, F., Pradier, O., Delporte, C., Van Antwerpen, P., De Maertelaer, V., & Cogan, E. (2016). Methylprednisolone-induced lymphocytosis in patients with immune mediated inflammatory disorders. The American journal of medicine, 7(129), 746-752. doi:10.1016/j.amjmed.2016.02.01338.
Sauvage, D., Roufosse, F., Sanoussi, I., Massin, M., Rooze, S., De Ville, A., Azzi, N., Huybrechts, S., Dedeken, L., Devalck, C., & Ferster, A. (2015). Treatment-refractory hypereosinophilic syndrome responding to fludarabine in a 12-year-old boy. Leukemia & lymphoma, 56(9), 2711-2713. doi:10.3109/10428194.2014.1003058